~~SPECIFICATION~~

TRANSGENIC MAMMALS

5   TECHNICAL FIELD

This invention provides transgenic mammals. Particularly, the invention provides the nonhuman transgenic mammals carrying the human complement-inhibitor (hDAF/CD55) gene. More particularly, the invention provides domestic and laboratory animals carrying the hDAF gene.

10

BACKGROUND OF THE INVENTION

Recently, studies on animal-to-man organ transplantation (xenotransplantation) have been carried out mainly in European countries and the United States. Because of close relation to human beings, apes may be

15   desirable donors, but the use of their organs may be infeasible because of the shortage of these animals and their high intelligence. However, domestic animals, particularly pigs, have advantages of their organ sizes and shapes similar to those of man, easy supply due to mass rearing and established basic technology. Consequently, organ transplantation from the pig to man has

20   mainly been studied.

If a porcine organ is transplanted to man, it will immediately (within minutes) and severely be rejected (hyperacute rejection), resulting in loss of its functions.

These phenomena are thought to be caused by a series of reactions: (1)

Human blood contains endogenous antibodies against porcine cells (termed natural antibodies). If a porcine organ is transplanted to man, such antibodies recognize the porcine organ and form antigen-antibody complexes. (2) The antigen-antibody complexes activate complement in human serum and trigger the complement cascade reaction. The attachment of C1 to the antigen-antibody complexes triggers reactions of C4 and C2, resulting in formation of C3 convertase, which activates C3 and cleaves it to C3b and C3a. The attachment of C3b to the cell surface of the porcine organ results in formation of C5 convertase, which activates C5 and cleaves it to C5b and C5a. The attachment of C5b to the cell surface results in sequential attachments of C6, C7, C8 and C9. (3) In consequence of the complement cascade reaction, the membrane attack complex (MAC) is formed (termed the classical complement pathway). MAC attaches the transplanted organ and causes thrombosis. (4) The alternative complement pathway is known to cause also the same cascade reaction as described above after the C3 step and finally to form MAC.

Miyagawa, S. *et al.* (Transplantation, Vol. 46(6), 825-830, 1988) reported the following: (1) the complement cascade reaction triggered hyperacute rejection of xenografts via the classical and/or alternative pathway; (2) no hyperacute rejection occurred, if the recipients had previously been treated with CVF (cobra venom factor) to cause deprivation of C3. From such findings, it has long been desired to generate transgenic animals expressing membrane-bound DAF and/or MCP, especially those homologous to recipient species, which can inhibit the cascade reaction at the C3 step.

It has been tried to generate transgenic pigs expressing a complement

inhibitor hDAF (CD55) to decompose human C3 convertase in the porcine

organs (Rosengard, A. M. *et al.*, Transplantation, Vol. 59(9). 1325-1333, 1995: G.

Byrne *et al.*, Transplantation Proceedings, Vol. 28(2), 759, 1996).

However, it has never been explained whether these transgenic pigs

5   completely suppresses hyperacute rejection. Therefore, questions like the

following should be answered: 1) Do these transgenic pigs express sufficient

amounts of hDAF in target organs? 2) Is it necessary to co-express some other

complement inhibitors? 3) Isn't it necessary to express sugar- transferase gene

in order to reduce the antigen (sugar-chain antigen), which is expressed on the

10   porcine cells and to which human natural antibodies bind? 4) Isn't it necessary

to co-express the above-described gene and other genes encoding the

thrombosis-preventing protein and the like? Thus, many problems are left

unsolved to overcome the hyperacute rejection.

To solve these problems, it is urgent to generate pigs and/or other small-

15   sized laboratory animals that can be handled more easily than pigs and to

examine these animals from various viewpoints. Particularly, in order to carry

out studies in this field and/or to develop clinical application, it is valuable to

generate transgenic pigs and/or small-sized easy-to-handle laboratory animals,

of which tissues and organs express hDAF of at least the same amounts as or

20   larger amounts than those expressed in man.

Therefore, it has been tried to generate transgenic pigs expressing the

human complement inhibitors as described above. Expression was examined by

such methods as the following; (1) *in vitro* immunohistological examination, (2)

ex vivo examination by allowing the transgenic pig tissues to contact directly

with human blood, or (3) *in vivo* examination by transplanting the transgenic pig

tissues to primates. It was confirmed that the tissues from the transgenic pigs

survived and functioned longer than those from nontransgenic pigs in *ex vivo*

and *in vitro* examinations.

5   However, it was not necessarily explained whether the amounts of the

human complement inhibitors expressed in the transgenic pig tissues were at

least equivalent to or larger than those expressed in man.

       To generate transgenic pigs expressing the human complement inhibitors,

the following have been reported as the promoter genes of transgenes: (1) the

10   promoter genes from nonporcine sources (G. A. Langford *et al.*, Transplant.

Proc., 26, 1400, 1994; W. L. Fodor *et al.*, Proc. Natl. Acad. Sci. USA., 91,

11153-11157, 1994; G. W. Byrne *et al.*, Transplantation, 63, 149-155, 1997)

and/or (2) the promoter genes relating to molecules distributed throughout the

whole bodies of animals (*e.g.*, beta-actin, H2K^b).

15   Transgenic mice expressing hDAF have also been generated (N. Cary *et al.*,

Transplant. Proc. Vol. 25(1), 400-401, 1993; D. Kagan *et al.*, Transplant. Proc.

Vol.26(3), 1242, 1994). The loci and amounts of hDAF expressed in these

transgenic mice, however, varied from report to report. Strictly speaking, no

transgenic mouse expressing the human complement inhibitor in the due organ

20   to develop it (particularly, vascular endothelial cells) in an amount larger than

that expressed in human organ has ever been generated.

       To solve the above problems, the present inventors studied to generate

transgenic animals, particularly those other than man, expressing complement

inhibitor(s) in the due organs, tissues and cells, particularly the vascular

endothelial cells, in which the complement inhibitors should essentially be expressed. The inventors succeeded in generating transgenic animals fulfilling the purposes with the promoter gene of the porcine complement inhibitor (pMCP) previously invented by the inventors (see Japanese Patent Application

5 No. 142961/1997), by introducing the transgene designed to express the complement inhibitor(s) in the due organs, tissues and cells, particularly in the vascular endothelial cells, in which the complement inhibitors should essentially be expressed, into animals' fertilized eggs, by implanting the eggs in the uteri of recipient animals and by obtaining their youngs.

10 The examples described below show that the transgenic mice of this invention expressed hDAF in various organs, tissues, endothelial cells, erythrocytes, and central and peripheral nerves in amounts larger than those expressed in human cells. Furthermore, the expression of hDAF was confirmed in their erythrocytes and nerves of the transgenic pigs of the invention.

15 This invention was accomplished on the basis of such findings. The purpose of the invention was to provide transgenic animals useful in the medical and pharmacological fields.

DISCLOSURE OF THE INVENTION

20 This invention is related to nonhuman mammals carrying the human complement inhibitor (DAF/CD55) gene and expressing the inhibitor in their organs and tissues. Furthermore, the invention is related to transgenic mammals expressing the human complement inhibitor (DAF/CD55) in their vascular endothelial cells, particularly in those of all the organs and tissues.

It is favorable that the transgenic mammals of the invention are carrying the promoter gene of the porcine complement inhibitor (pMCP) at an upstream locus of the human complement-inhibitor (DAF/CD55) gene.

The transgenic mammals of this invention are useful as domestic and laboratory animals.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates the structure of the transgene comprising pMCP promoter (5.4 kb) and hDAFcDNA.

Figure 2 illustrates the structure of the transgene comprising pMCP promoter (0.9 kb) and hDAFcDNA.

Figure 3 illustrates the structure of the transgene comprising hDAF promoter and hDAFcDNA used for comparison.

Figure 4 shows the PCR profiles obtained by examining the transgenic and nontransgenic mammals with hDAFcDNA-specific primers.

Lanes (1) and (3) of Fig. 4 show the PCR profiles of the hDAFcDNA-possitive pig and mouse, respectively. Lanes (2) and (4) show those of the hDAFcDNA-negative littermate pig and mouse, respectively.

Figure 5 shows expression of mRNA of hDAF in various organs of a TgF1 mouse, a transgenic mouse generated for comparison and a normal mouse (nontransgenic mouse).

Expression of mRNA in various organs of the TgF1 mouse is shown in Fig. 5(A); that of the transgenic mouse for comparison (generated by introducing transgene (3) comprising hDAF promoter and hDAFcDNA) (see Fig. 3) is shown

in Fig. 5(B) ; that of the nontransgenic mouse is shown in Fig. 5(C) and that of

human lymphocyte (K562) at the right end of Fig. 5(C). B, H, K, Li, Lu, S and T in

each figure stand for the brain, heart, kidney, liver, lung, spleen and testis,

respectively.

5   Figure 6 shows FACS-analysis profiles obtained by treating erythrocytes

from a transgenic pig and its nontransgenic littermate pig with anti-hDAF

monoclonal antibodies. Figure 6(A) shows that the erythrocytes from the

transgenic pig expressed hDAF, whereas Fig. 6(B) shows that those from a

nontransgenic littermate pig did not.

10   Figure 7 shows hemolysis profiles obtained by treating erythrocytes from

the transgenic (●) and normal (■) animals with human serum. Figures (a) and (b)

show the hemolysis profiles of the mouse and porcine erythrocytes,

respectively. The horizontal and the vertical axes of the figure represent the

complement concentration in human serum and the degree of hemolysis,

15   respectively.

THE BEST MODE FOR APPLYING THE INVENTION

        As described above, the present invention provides nonhuman transgenic

mammals carrying the human complement inhibitor (referred to as hDAF in the

20   following) and expressing the inhibitor in their organs and tissues, particularly in

the vascular endothelial cells. As far as it is other than man, the species of

mammals of this invention is not restricted. Examples of mammals are the

mouse, rat, hamster, pig, cattle, horse, sheep, rabbit, dog, cat and so on.

        Transgenic mammals of the invention can be generated by the following

methods:

First, transgene is prepared by binding promoter gene with hDAFcDNA. A part of an appropriate vector (e.g., pGL-3 basic vector, pBluescript and the like) is clipped out with a restriction enzyme(s), and the ends of the digested vector

5   are truncated.

Base sequence encoding hDAF is clipped out from hDAFcDNA (see Medof, M. E. *et al.*, Proc. Natl. Acad. Sci. USA., 84, 2007, 1987 for example) at an upstream locus of the initiation codon and at a downstream locus of the termination codon with a restriction enzyme(s), truncated and conventionally

10   inserted into the above-described vector. An appropriate promoter gene is also inserted at an upstream locus of the hDAFcDNA-introduced locus.

Any promoter can be used, as far as it can induce expression of hDAF in the mammals' bodies. A promoter gene of endothelin is an example. The inventors found that a promoter gene of porcine complement inhibitor (pMCP) worked

15   more efficiently. The base sequence of the promoter gene of pMCP is defined as Sequence No. 1 (see Japanese Patent Application No. 142961/1997).

From the vector thus prepared (circular gene), transgene is prepared by digesting the region including the promoter and hDAF genes with an appropriate restriction enzyme(s).

20   Methods to carry out the above-described processes are commonly known by those skilled in the art. The processes can conventionally be performed.

Transgenic mammals can be generated conventionally by introducing by microinjecting the above-described transgenes into mammals' fertilized eggs (those at the pronucleus phase), implanting the eggs in the oviducts of female

mammals (recipient mammals) after a few additional incubation or directly in their uteri synchronized to the pseudopregnancy, and obtaining the youngs. If the pronuclei are hard to be recognized because of the presence of many fatty granules in the eggs, they may conventionally be centrifuged.

5   To find whether the generated youngs are transgenic, below-described dot-blotting, PCR, immunohistological, complement-inhibition analyses and the like can be used.

The transgenic mammals thus generated can be propagated by conventionally mating and obtaining the youngs, or transferring nuclei (nucleus

10   transfer) of the transgenic mammal's somatic cells, which have been initialized or not, into fertilized eggs of which nuclei have previously been enucleated, implanting the eggs in the oviducts or uteri of the recipient mammals, and obtaining the clone youngs.

As shown in the below-described examples, it was confirmed that the

15   transgenic mammals of this invention were carrying hDAF gene, expressing hDAF in the endothelial cells of all the organs and being resistant to the human complement.

INDUSTRIAL APPLICABILITY

20   The present invention is useful in the medical and pharmacological fields, exerting the following effects:

(1) If such organs as the heart, liver and kidney of the transgenic mammals of this invention are contacted with human blood or transplanted in primates, it can be confirmed that hDAF effectively prevents hyperacute rejection caused

by xenotransplantation.

(2) If the xenotransplantion model is prepared by contacting such organs as the heart, liver and kidney of the transgenic mammals of this invention with human blood or transplanting the organs in primates, the model will help

5 develop not only remedies, devices and the like to prevent hyperacute rejection after xenotransplantation but also those to prevent acute or chronic rejection after the hyperacute rejection.

(3) This invention makes it feasible to study hyperacute rejection-related problems hard to be solved only by expression of the complement inhibitors

10 themselves. Namely, the invention may answer the questions whether it is necessary to introduce sugar transferases to reduce expression of sugar-chain antigens to which human natural antibodies bind, and/or to introduce factors to maintain homeostasis of the vascular endothelial cells (*e.g.*, thrombomodulin, etc.).

15 (4) If the transgenic mammals of this invention are mated with those expressing some other complement inhibitor (human MCP or human CD59), synergic effects of the inhibitors can be examined.

(5) If the organs (*e.g.*, the heart, lung, liver, kidney, pancreas, etc.), their adjunctive tissues (*e.g.*, the coronary artery, endocranium, etc.) or cells (*e.g.*,

20 Langerhans islets producing insulin, nigrostriatal cells producing dopamine, etc.) from the transgenic mammals of this invention are transplanted to human patients whose organs have been damaged and their functions lost, they will supplement or substitute the functions of the patient organs.

(6) If the cells from the organs of the transgenic mammals of this invention

(*e.g.*, cells from the liver, kidney and the like, Langerhans islets producing

insulin, nigrostriatal cells producing dopamine, etc.) are cultured, put in an

appropriate device, and connected with human patients *ex vivo*, it will

supplement or substitute the functions of the damaged organs of the patients.

5

EXAMPLES

The present invention will specifically be explained in detail with actual

examples, but the scope of the invention is not restricted to these samples.

10   Example 1

①Construction of transgene

The transgene comprising pMCP's promoter gene and hDAFcDNA is

prepared as follows:

From pGL-3 basic vector (Promega), *luc* gene was clipped out at the *Nco*I

15   and *Xba*I sites. Both the ends of the digested vector were truncated with T4

DNA polymerase. Next, hDAFcDNA containing the first intron was clipped out at

an *Asc*I site of the upstream locus of initiation codon ATG and at an *Acc*I site of

the downstream locus of termination codon TAG, truncated with the T4 DNA

polymerase and inserted into the above-described truncated vector. Similarly,

20   an approximately 5.4-kb region corresponding to the promoter gene was

clipped out at the *Eco*RI and *Fsp*I sites from the porcine phage genomic library

containing pMCP gene (Japanese Patent Application No. 142961/1997), and

inserted into the *Eco*RI and *EcoRV* sites of the pBluescript vector.

(1) An approximately 5.4-kb promoter region inserted in the pBluescript

vector was clipped out at the *BstE*II and *Eco*RI sites (the sequence from the second to the 5,392nd bases of Sequence No. 1), truncated with T4 DNA polymerase (the sequence from the second to the 5,397th bases of Sequence No. 1), and then inserted into an *Sma*I site at an upstream locus of the above-

5   described hDAFcDNA-inserted vector. The region containing the promoter gene and hDAFcDNA was clipped out at the *Not*I and *Eco*47III sites and used as transgene (I) (see Fig. I).

(2) A 1.7-kb promoter region was clipped out at the *BstE*II and *Bss*H2 sites of upstream loci of the ATG initiation codon of pMCP, truncated with T4 DNA

10 polymerase, and then inserted into the *Sma*I site of the above-described hDAFcDNA-containing vector. The vector was clipped out at the pBluescript's *Bst*XI and *Spe*I sites located at further upstream loci of the promoter and linearized. The linearized sequence was digested with a Deletion Kit for Kilo-Sequence (Takara) to obtain a deletion mutant possessing the 0.9-kb promoter

15 gene (the sequence from the 4,498th to the 5,397th bases of Sequence No. 1). The region containing the above-described promoter gene and hDAFcDNA was clipped out at the *Not*I and *Eco*47III sites and used as transgene (2) (see Fig. 2).

(3) Transgene (3) comprising hDAF promoter gene and hDAFcDNA was

20 prepared as follows: hDAF promoter gene was prepared by clipping out an approximately 3.8-kb region corresponding to the promoter at the *Hind*III and *Asc*I sites, truncated and inserted to an *Sma*I site at an upstream locus of the hDAFcDNA-inserted vector. A region containing the above-described promoter gene and hDAFcDNA was clipped out at the *Not*I and *Eco*47III sites and used

as transgene (3) (see Fig. 3).

Each transgene was dissolved in phosphate-buffered saline (PBS) at 5 μ g/ml before used.

5 ② Generation of the transgenic mammals (mice)

The transgenes were introduced into mouse fertilized eggs and the transgenic mice were generated as follows.

CBA or C3H male and C57BL/6 female mice were mated to obtain baby mice, of which female mice (donor mice) were used to supply fertilized eggs.

10 The donor mice were mated with ICR male mice after inducing ovulation (by administration of PMSG and hCG). The fertilized eggs (at the prenucleus phase) were collected. The above-described transgene (1) or (3) was introduced by microinjection into the prenuclei until their swelling was confirmed. The transgene-injected prenucleus-phase eggs were implanted in the uteri of the

15 recipient mice immediately after transduction or in their oviducts after additional incubation for 3 days, and then baby mice were obtained. The recipient mice were made pseudopregnancy by mating them with vasoligated male mice.

20 ③ Generation of transgenic mammals (pigs)

The transgenes were introduced into porcine fertilized eggs and transgenic pigs were generated as follows.

Fertilized eggs were collected from hybrid female pigs (donor pigs) of Landrace, Large White and Duroc. After inducing ovulation of the donor pigs (by

administration of either PMSG or FSH, and hCG) and artificial fertilization with semen of male Duroc pig, the fertilized eggs (those at the prenucleus phase) were collected. After centrifugation (for 8 min at 12,000 x g) of the prenucleus-phase eggs, transgene (2) was introduced into the prenuclei until swelling was

5 confirmed. The transgene-injected eggs were immediately implanted in the oviducts of the recipient pigs, and then piglets were obtained. The recipient pigs were either pigs whose sexual cycle had been synchronized to those of the donor pigs by the above-described ovulation treatment or those from which the fertilized eggs had been collected.

10

④ Identification of the transgenic mammals

Genomic DNA was extracted from the tails of the youngs obtained from the recipient mammals and subjected to identification and selection of the transgenic mammals by the following two methods:

15 (1) The dot-blotting method: Genomic DNA (10 μ g) from the youngs was placed on a piece of membrane and hybridized with gene comprising a part of biotin-labeled hDAFcDNA. The transgenic mammals were identified by detecting the introduced transgene by an alkaline phosphatase-dependent photon-generating reaction (Sumalight, Sumitomo Metal, Inc.).

20 (2) PCR method: PCR was carried out (condition; denaturation for 30 sec at 94℃ and annealing for 2 min and 30 sec at 68℃, 30 times) with genomic DNA from the youngs as a template, 5'-GGCCTTCCCCCAGATGTACCTAATGCC-3' of hDAFcDNA as a sense primer and 5'-TCCATAATGGTCACGTTCCCCTTG-3' as an antisense primer. The transgenic mammals were identified by detecting the

introduced transgene. The results, shown in Fig. 4, confirmed that some of the

youngs obtained from the recipient mammals carried hDAFcDNA in their

genome. Lanes 1 and 3 of Fig. 4 show the results with the hDAFcDNA-carrying

pig and mouse, respectively. Lanes 2 and 4 of Fig. 4 those of hDAFcDNA-not-

5 carrying littermate pig and mouse, respectively.

⑤ Propagation of the transgenic mammals (mice)

The mice confirmed to be transgenic were mated with ICR mice, and then

baby mice carrying the transgene were generated (termed TgF1 mice).

10

⑥ Confirmation of expression of the transgene (transcription of mRNA) in the

transgenic mammals (mice)

By the conventional RT-PCR method, mRNA from various organs of the

TgF1 mice was examined for transcription of hDAFcDNA. For comparison,

15 mRNA from those of the transgenic mice generated with transgene (3)

comprising hDAF promoter gene and hDAFcDNA and mRNA from those of

normal mice (nontransgenic mice) were similarly examined for transcription of

hDAFcDNA. The results are shown in Fig. 5. B, H, K, Li, Lu, S and T in Fig. 5 stand

for the brain, heart, kidney, liver, lung, spleen and testis, respectively.

20 With the transgenic mice generated by introducing transgene (1)

comprising pMCP promoter gene and hDAFcDNA (see Fig. 1), strong signals

indicating transcription of mRNA of hDAF were confirmed in all the organs

examined (the brain, heart, kidney, liver, lung, spleen and testis) (Fig. 5A).

With the transgenic mice obtained by introducing transgene (3) comprising

hDAF promoter gene and hDAFcDNA (see Fig. 3), a signal of mRNA of hDAF was

observed only in the testis, whereas no or faint signal in other organs (Fig. 5B).

With the nontransgenic mice, no transcription of mRNA of hDAF was

observed in any organ (Fig. 5C).

5   With a cell line of human lymphocyte (K562), transcription of mRNA of

hDAF was confirmed (the right end of Fig. 5C).

⑦ Confirmation of expression of the transgene in the transgenic mammals

(mice) (confirmation of expression of hDAF protein by an immunohistological

10   method)

Frozen sections of the TgF1 mouse organs were prepared and treated with

biotin-labeled anti-hDAF monoclonal antibodies and then peroxidase-labeled

streptavidin. After reaction with a chromogenic substrate (diaminobenzidine;

DAB), the sections were microscopically examined for the intensity and the

15   locus of the expressed hDAF protein. The results are shown in Table 1.

With the transgenic mice generated by introducing transgene (1)

comprising pMCP promoter gene and hDAFcDNA, it was confirmed that all the

organs examined were intensively expressing hDAF. The organs expressing

hDAF were artial and ventricular myocardia, and endothelia of medium, small

20   and capillary blood vessels of the heart, glomerulus, uriniferous tubule, and

endothelia of medium, small and capillary blood vessels of the kidney,

hepatocytes, epithelia of bile ducts, and endothelia of medium, small and

capillary blood vessels of the liver, alveolar wall, bronchioles epithelium, and

endothelia of medium, small and capillary blood vessels of the lung, epithelia of

intestinal mucosa, and endothelia of medium, small and capillary blood vessels

of the intestines, exocrine glands, Langerhans islets, epithilia and endothelia of

medium, small and capillary blood-vessels of the pancreas, white and red pulp,

trabeculare lienis, and endothelia of medium, small and capillary blood vessels

5   of the spleen, cerebral and cerebellar cortex and medulla, and endothelia of

medium, small and capillary blood vessels of the brain, seminiferous epithelia,

interstitial cells, sperms, and endothelia of medium, small and capillary blood

vessels of the testis and peripheral nerves.

With the transgenic mice generated by introducing transgene (3)

10   comprising hDAF promoter gene and hDAFcDNA, the expression of hDAF was

confirmed only in the testis, but not in the endothelial cells of the testis.

15

20

Table 1

Organ		Promoter gene used to generate transgenic mouse		Normal mouse
		pMCP	hDAF	
Heart	Artial myocardium	+ +	−	−
	Venticular myocardium	+	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Kidney	Glomerulus	+ +	−	−
	Uriniferous tubule	−	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Liver	Hepatocytes	±	−	−
	Epithelia of bile duct	+ +	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Lung	Alveolar walls	+ +	−	−
	Bronchioles epithelium	+ +	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Intestines	Epithelia of intestinal mucosa	+	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Pancreas	Exocrine glands	+	−	−
	Langerhans islet	+	−	−
	Epithelia of pancreatic ducts	+	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Spleen	White pulp	±	−	−
	Red pulp	±	−	−
	Trabeculare lienis	+	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Brain	Cerebral cortex	+ +	−	−
	Cerebral medulla	+ +	−	−
	Cerebellar cortex	+	−	−
	Cerebellar medulla	+ +	−	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
Testis	Seminiferous epithelia	+ +	±	−
	Interstitial cells	+	±	−
	Sperms	+ +	+ +	−
	Endothelia of medium, small and capillary vessels	+ +	−	−
	Peripheral nerve	+ + +	−	−

⑧ Confirmation of expression of the transgene in the transgenic mammals
(pigs) (confirmation of expression of hDAF protein by an immunohistological
method)

Expression of hDAF protein was observed in the pigs which had been
identified to be transgenic by the PCR method as described in ④.

Frozen sections were prepared from the tails of the pigs and treated with
biotin-labeled anti-hDAF monoclonal antibodies and then peroxidase-labeled
streptavidin as described in ⑦. After reaction with the chromogenic substrate
(diaminobenzidine; DAB), they were microscopically examined for the intensity
and the locus of the expressed hDAF protein.

Expression of hDAF was confirmed in the medium, small and capillary
blood vessels of the transgenic pigs generated by introducing transgene (2)
comprising the pMCP promoter gene and hDAFcDNA. Besides, expression of
hDAF was confirmed also in such organs as the peripheral nerves, skeletal
muscle, and stratified squamous epithelia of the skin.

⑨ Confirmation of expression of the transgene in the transgenic mammal (pigs)
(confirmation of hDAF-protein expressing by FACS analysis)

To examine for hDAF-protein expression, the organs of the transgenic pigs
which had been identified to be transgenic by the PCR method as described in
④ and by the immunohistological method as described in ⑦ were subjected
to FACS analysis (a fluorescence-activated cell sorter, Becton Dickinson's
FACScan) with anti-hDAF monoclonal antibodies.

An erythrocyte fraction was prepared from blood of the transgenic pig,

treated with the biotin-labeled monoclonal antibodies and then Phycoprobe PE Streptavidin (Biomeda), and subjected to FACS analysis. The results are shown in Fig. 6 (A). Similar analysis as described above was carried out with a nontransgenic littermate pig. The results are shown in Fig. 6 (B). The horizontal

5   and vertical axes represent the intensity of fluorescence indicating the amount of hDAF expressed and the cell number, respectively.

As shown in Fig. 6, it was confirmed that the erythrocytes from the transgenic pig identified by PCR and the immunohistological methods expressed huge amounts of hDAF, but that those from the nontransgenic pig

10   did not.

Figure 6 shows also that the transgenic pigs of this example simultaneously possessed erythrocytes expressing hDAF and those not expressing hDAF (referred to as mosaic) . It has already been shown that the first generation of the transgenic animals (founder) generated by the microinjection method

15   sometimes become mosaic, and that such mosaic may disappear by such conventional methods as mating and breeding.

The results shown in ⑧ and⑨ confirmed that the transgenic pigs generated by introducing the transgene comprising pMCP promoter and hDAFcDNA expressed hDAF from hDAFcDNA in various organs and tissues

20   including endothelial cells.

⑩ Confirmation of expression of the transgene in the transgenic mammals (confirmation of the function of hDAF protein)

It was confirmed that the hDAF protein expressed on the transgenic

mammals' cells had the essential function of hDAF protein, *i.e.*, suppression of the complement cascade reaction. Confirmation was accomplished by determining hemolysis occurring after treating the transgenic mammal's erythrocytes with human serum. The erythrocytes were subjected to such

5 analyses, since the complement cascade reaction could be identified by observing hemolysis (1) easily due to formation of membrane attack complex, and (2) clearly due to more fragile membrane structure of erythrocytes than other cells (*e.g.*, leukocytes, endothelial cells and the like).

The erythrocyte fractions were prepared from blood specimens taken from

10 the transgenic and nontransgenic mouse tails and those taken from the transgenic and nontransgenic pig ear veins. After diluting the fractions with PBS, a 30-μl portion of each fraction was placed in a well of 96-well microplates (1 x 10^7 cells/well), to which a 70-μl portion of complement concentration-adjusted human serum (which had been prepared by blending

15 human normal serum [HNS] and previously inactivated serum (by heating for 30 min at 56℃) [HIS]) was added dropwise and then allowed to react (for 1.5 h at 37℃). Optical density of the supernatant of each well was read at 405 nm with a microplate reader (Bio Rad), and the per cent hemolysis caused by the complement cascade reaction was calculated.

20 The results are shown in Fig. 7, in which figures (a) and (b) respectively show the results with the mouse and porcine erythrocytes. The horizontal and the vertical axes represent the concentration of HNS in human serum and the degree of hemolysis, respectively. Symbols ● and ■ in Fig. 7 show hemolysis of the erythrocytes from the transgenic and the nontransgenic animals,

respectively.

Such hemolysis occurs (1) since co-existence of animal erythrocytes and human serum immediately triggers the classical complement pathway due to the presence of the natural antibodies and complement in human serum, and (2) since animal erythrocytes (excluding the transgenic mammals of this invention) cannot inhibit human complement cascade reaction due to the species-specificity of the complement inhibitor.

As shown in Fig. 7, the erythrocytes from nontransgenic animals underwent hemolysis irrespective of the complement concentration in human serum, whereas those from the transgenic mammals inhibited hemolysis. These findings confirmed that the erythrocytes expressing hDAF from the transgenic mammals were resistant to human complement. Although the erythrocyte population of the transgenic pigs of this invention was mosaic, it was resistant to the human complement.

SEQUENCE TABLE
Sequence number: 1
Length of sequence: 5,418
Type of sequence: nucleic acid
5   Number of chains: double strand
Topology: linear
Kind of sequence: Genomic DNA
Direct origin: λ FIXII porcine genome phage library
Sequence

```
10   GAATTCTGCG TACACGGGGC CCCGGTGGCT TTACATCATC GCTACAGCGA    50
     CATGGGATCC GAGCCGTGTC TACAACCTAC ACAACAACGC CAGATCCTTA   100
     ACCCAATGCA TGAGGACAGG GCTCAAACCT GCGGCCTCAT AGATGCTAGT   150
     CAGATTCGTT TCTGCTGAGC CACAATGGGA ACTCCTAATT CTAGATCGAT   200
     CTAGAATTAG GAGTTCCCAT TGTGGCTCAG CAGAAACGAA TCTGACTAGC   250
15   ATCTATGAGG CCGCAGTTTG AGCCCTGTCC TCATGCATTG GGTTAAGGAT   300
     CTGGCGTTGT TGTGTAGGTT GTAGACACGG CTCGGATCCC ATGTCGCTGT   350
     AGCGATGATG TAAAGCCACC GGGGCCCCGT GCTACGCAGA ATTCNTGCAG   400
     CCCGGGGGAT CCACTAGTTC TAGCNAGAGA GTTGAAAATT TAAAGAACAT   450
     TTCTCCCCTA ATCTCCCAAA ATATGGGCAA AGGACAGGTA CCCGTGGCAC   500
20   TGGAAAAATA CAGGCAAGCA ACCCATGAGT ACATGAAAAG ATGCTCCAGG   550
     GTTCGGCCTA ATGGAAGCCT GAACAATGCC TATCACATCG TGGGTTTCTG   600
     AAGAAGTAAC TTAAAGAAAC TAGAAATTAA ATGGCTTTCT TAGAATGAAA   650
     ATTCTCTATC ACAAGGAAAA ATGTTGTATG TTGTTTTTCC CATAATGGAG   700
     GTCAGTGGGC GCTATGATTA ACAAATATCT GATGCCTGTG ACTTTTTAAT   750
25   TGCAAGAAAT CTGTGNAGTT TTTTTATTAT CTATGGGAAA TATTGCATAT   800
     ATTAATGATA TCACCTAACT TGTATTATTG AGCAATTCTG TCCACATCTG   850
     GCCTTTCATC TTTCATCTAA AAAGCAGGGG CTGGACCAAC TGACCTTCAG   900
     TGCCATTCTT ACTGCTAACA TTCTAATTTT GTTTTTATTG CCTTTTTGTA   950
     CAAAAGTGTG AGAGAAGTCA TTTTAAGTCT GTGACATTAA ATGTAATTTT  1000
30   CTGTCTCCAG CATTATAATA AGAATCAAAG ATTTAATCTA ATACACCGAT  1050
     GGAATATTGT TTATAACGTA TTTACTGTTT CAAGCCTTCA AAACCAAGAG  1100
     AAAACAAAAT GAGTACCTGT TCCTTCTGAG AAATGCCCTT CTTCCTGTTC  1150
     AGAATCCCTG TGTATAACAG GAATGCTCTC GAGTTAACAG CCAAGTAAGA  1200
     GGCCCATCGG CTGGCAGGTG CCCACCTAGC TAGGTGCAAG CAGAGGTGGC  1250
35   AGTGCTCCCA GGACCAACAG CAGAAACATG GCTTAACTAT CCTGTGTTTA  1300
     GCAGTTCTCT TACGGGTTTT CACAACACCT AAAAAGCGCC CTGATGGGGT  1350
     AAAGCCTCTG CCTTCATGCT GCTGCCCCGT CTCTGAAAAG CAGGACGTAA  1400
     ATATACAATT TAGGAGGTAA GAGGGACATC TGCCATTGTT TTCTTTAACA  1450
     CAGTCAGCCT CTGTTTAATG AATCCCAGCC ACCTCCCTCC ACCTACCATC  1500
40   ATTCCTAAGG TTTGCAGAGG AGCTGCCATA GAGCTCAAAA CACGGWNTAC  1550
```

```
        AGACAAGCAT NTTCTCCATC CCTCCTCATC TTCTCACAGG CCGCTTGACA  1600
        ACATCTCTAG GAGGGGGTGG AGGCGCCACC AGTGTTTGAG CCCCTCGTTC  1650
        ACGCAAAGCC TTGACTCTGG AGTTCTAGTC CTCGCGGGAC CTTAGGAAGT  1700
        TCACGGTCAA TACTCCGCCC TTGGGCTCAG ACACTAAGAG GATCTCCGGG  1750
     5  TAAAGAGATA GACAGTAGCT CCATGCCTGA TTTAGGAAAA CTGTCCGTAC  1800
        AGACAGTTGT AATTCATTCC TTTCAGAGAC AAATCCTGCT CTCTTCCTAG  1850
        TTCCTGAAGT CATTAAAATC AAAAGCTCTC AGAAACGTCC CAGCATTTGC  1900
        TAAGTCCACG CTGGGGGAGG ATGGGCAGAG CCGTGTTCAG CGCGTTTGAC  1950
        AGCAACACCC ACTTATTTCA TTYAGTATCC ATAGGCATAT ATCATGCACC  2000
    10  TGGTATAGGC CTCTCTCTCA GCACTGGAGA TACAGCAAGA AAACGCTATT  2050
        CCTGCCCCAT GGAGCTTGTW MARAAAAATA GANNNAAAAA CCCTTTANAA  2100
        ANGGAAGCTR CCNGMTGGGN CMAAGTNAAA ATTAAGTAAA AAGAAAWCCG  2150
        TGARRAAACC CTTCAGTNAT ATTAAGAAAG AAANTAGCTT GATGAAACCC  2200
        CAGGTGTANA AATTNNCACT AAAACAATGS TCCCAATTAA AACCCCCMAA  2250
    15  TTCATGGAAT TTACTCNAGT ANCCTGNAAC TAGGRAAACC AAATTCTAGC  2300
        CNATAGTTTC TCCCTTCTAA ATNTTCTCAT GAGAAAACAA YTTATTTCCA  2350
        AAGANATTTT CCATGATGGG GAAAGTTTTT TTCAACTTTG CTCAGGTATA  2400
        AACTGAANAT ACAGCATTAA AGTAAAGATA GTTGCAGAGA CCACCAAATA  2450
        GATACCCGTT TTCANAAAAA GTGCCAACAT GGAGCCAGAG AACATTTCCG  2500
    20  TTACATCACG CTTTTACGGC TTTGAAAATT AACAGAGATG ATAATCCCCC  2550
        MCCTTGGGTT TCCNACTCCN TCCCTCCTNA ATTTTACCTC CTTTAATTGT  2600
        CATCATGTCT GGAGATTATA ATCCAAGATA CTAAGATGTT TATNTCATAC  2650
        ATCGCCTCCA CACAGTGTGT CTNANAAGCT CTTGCAAGAA TCCAAACATT  2700
        GTGCTGGTCT GGGTAGAAAA GGAAATTCCA TGGTTTGTTG AACCCAGGAA  2750
    25  CTCTTCAGTA CATCTCCGAG GTAAAACTGT TTAAATACAA TTAAAGTTCT  2800
        ACAGTTAAAG GGTACCCTCC TCCACTGTTG GTGGGAATGT AAACTGGTAC  2850
        AATCACTATG AAAAACAGGA TGGAGGTACT TCAGAAAATG AAGTATAGAA  2900
        CTACCACAGG ATCCAGCACT CTCACTCCTG GGCACCTATC AGGACAAAAA  2950
        ATTCGCTGCA AAAGATGCAT GCACCCATAG CTATGTTCAC TGCAGCAGCA  3000
    30  TTCACAATAG CCAAGACATG GAAACGACCT AAATGTCCAT CAACAGCTGA  3050
        ATGCATTAAG AAGACGTGGT ATATACACAC AATGGAATAC TACTCAAGTC  3100
        ATGAAAAAGA ACAAAGAAT GCCATTTGCA GCAACATGGC ATGGCTGGAA  3150
        CTAGAGACTC ATGCTAAATG AAGTCAGTGA GAAAGAGAAA GACAAATACC  3200
        ACATGATATC ACTTATATCT GGAATCTAAT ATACGACACA CATGAAACTT  3250
    35  TCCACAGAAA AGAAAACCTN CATGGACTTT GGAGAACAGA CTTGTGGTTT  3300
        CSCCAAGGGG GGARGGGGGG AAGACCGTGG GAGGACTGGG GAGCTTTGGG  3350
        GTTAATAGAT GCAAAACTAT TGCCTTTNGA ATGGATAAGC CAATGGGATC  3400
        CTGCTGTACC AGAACCRGGG AACTATANCT AGTCACTTGC KNTAGAACAT  3450
        GATGGAGGAT NATNTGAGAN AAAGAATATN TGTGTGTGTK AGAGAGAGAG  3500
    40  AGACTGGCTC CACTTTGCTG TATAGTAGAA AACTGACAGA ACACCGTAAA  3550
```

```
     CCATTAAATA AAAATCCAGT AAAAATTTAA AAATAAAAAC ACACATTGGT   3600
     TCCAATGTGT TTAAAAGCAA TAAAGTTCTA TAATTGCAGC AGATGCATCT   3650
     GAGGTTTACA CGGAGAGCTT CCATTCCTTA CCATCCTCTC ATTCCTTAAC   3700
     TCTAATGTGA TACAGGTTCT ATTCTCACCA TTCTATGAAC AAAAGAGCAG   3750
 5   CTGATTTACA GGTTGGATTT TTCAAAAAAA AAAATTTCTT TACCAGGATC   3800
     CCAAATGTAA CAAAGGGTCA ATATAGAAAA CTTAAAAAGC ACAGCCAAAG   3850
     AGAAATATAC ATAAGCCTTT CAACTATTAA TTTTGATTAA TATCCAACGA   3900
     ATCTCTTTTT AAGTGTATCA ATATATTATT CATTTTAATA AAAGAAATTG   3950
     CAAGAGGCAC TTGCTTTTTC TGCTTACAAA TACGGTTTCT CAAATCGATT   4000
 10  TTTTTTATAT ACTGTTTGCA TAGAATTTCA ATCCATAAAG CTACCTATTG   4050
     AAAATTCCTT ATATTTCTGC TAAACACTTA AGGGCTTATA TTTTCTCCAA   4100
     ATTTATACAT CCTTGCTCAC AGTTCTGACG ATGTCTTTGG GATAAACTCT   4150
     AAATGGAACT AGAGGTTTAA AAGTTATGTC CATTTAAAAC TTTTAACACA   4200
     AAAAAAGGTA AGTTAAAAAG TAAAAGTTTG GGGAGGCTGC TGGTCGCCCC   4250
 15  CCCAACATTG GCTGACATTT TTATTCTTTG ACAACAAATA GGAAGAAAAT   4300
     GTCAATGTCT TTTTTTACTG CTTAATACTG GTCATGTTAC TTTTCTTTCC   4350
     TTTTGCTAAT CATACAGGCT TACTCACAAC TCTACAAAAA AATCTTACTC   4400
     ATTCCTAATG TTCCTTCATT GAGAGATTGG TTTGCCGGAA ACGTTCTCAC   4450
     TCTCACCAAG TCCCAACAGT CCCAACTCTA ACGACGGTCG CTGCTTCCAG   4500
 20  AAATACGGCA CTTAAGGCAC CCTCGTCCTT ACCTTTTTCA TGCATGTGTA   4550
     TTTCATTTTC AATAAAACAT TGAGTTGTTC CAAGGCCAGA CCATAGAGTT   4600
     GAGCCCCAAC ATGCTAGTGG CCCAGTGTGA TGTAATAATT TACCTTCCCA   4650
     GGGGTCCTCT CCGGGGGGGT ACAGGCGAGA CTAAGTGACT TTAAGCTGTT   4700
     GGGAGAACAA TGGCCAAACC TTTCGTGATT TTGAAATCTA TCAGGCCACG   4750
 25  AGACACTTCG GTAGCGGACG CTCAACCCTG GGAATCCCAA CTATTGTCCC   4800
     AAATTTTGCC TGACTCGTGC CAAAGATTGA GCCAGGGCCC GGGTGTCCAG   4850
     GCAGTCTGCA GTGCCCCAGT CCCCACCAGA GCCCTGAAGG GTGTCGGGCC   4900
     CCACGAAACC GCTGCCCGGG CTCTAGGGTT TCTGTTTTCA GGTCGCTGCG   4950
     CTTTATTCTC TAATTCAGCG TTCCCGAAAG AGACCATGAG GACCCGCCCA   5000
 30  GTGTCCTTTA CACCTTCCCG TGTCGGGTGG CGACAGCTGT TTACGAAGAA   5050
     GAGTGCACCA CCCTTTCCCG CAAGCCGCAG CGGTTAGTTC CGCAGAAGGA   5100
     GGAGCCAGGG CGTCGGGCCG CAGCTGGGAG AGAGGCCCGG CAGCGGGCGC   5150
     CGCGGAGCAG CAAGGGCGTC CCTCTCTCGG CCGGAGCCCC GCCCCGCCCC   5200
     GCCCCCACGG CCCCGCCTTG CGGCCCGCCC ATTGGCTCCG CCGGGCCCTG   5250
 35  GAGTCACTCC CTAGAGCCAC TTCCGCCCAG GGCGGGGCCC AGGCCACGCC   5300
     CACTGGCCTG ACCGCGCGGG AGGCTCCCGG AGACCGTGGA TTCTTACTCC   5350
     TGCTGTCGGA ACTCGAAGAG GTCTCCGCTA GGCTGGTGTC GGGTTACCTG   5400
     CTCATCTTCC CGAAAATG                                      5418
```